BBIO Stock — BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. (BBIO)

Updated October 16, 2026.

BBIO is a Stock. Total return is 141.0% over the past 7.3 years, 49.7 points behind SPY at 190.7%.

BridgeBio Pharma is a biopharmaceutical company that discovers, develops, and delivers medicines for patients with genetic diseases, with a pipeline including treatments for cardiomyopathy, rare metabolic disorders, and genetic conditions like achondroplasia and Canavan disease. The company does not currently distribute dividends to shareholders. BridgeBio appeals primarily to investors seeking exposure to early-stage drug development and genetic disease therapeutics rather than those focused on generating current income.

BBIO performance versus SPY

Price and return data through 2026-10-16.

Total return is 141.0% over the past 7.3 years, 49.7 points behind SPY at 190.7%. Over the past year its total return — price change plus distributions reinvested — is 20.6%. Its deepest 1-year drawdown was 29.8%.

BBIO key facts

Asset type

Stock

Asset class

Equity

Inception date

06/27/2019

Distribution frequency

None

Last close

$66.39 (as of 2026-10-16)

Market cap

$12,978,780,071

Average volume

2055506.0

Beta

0.972

Payout ratio

0.0%

EPS

$-3.77

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BBIO risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 29.8%.

Who may consider BBIO — and who may not

It is a weaker fit for investors who need monthly cash flow (BBIO does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BBIO

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions